Communiqués BioNexus Gene Lab Corp.

Actions

BGLC

US0906283066

Recherche biotechnologique et médicale

Temps Différé Nasdaq 15:56:10 19/08/2026			Varia. 5j.	Varia. 1 janv.
1,570 ^USD	+1,95%		+1,29%	-60,25%

14/08	BioNexus Gene Lab Corp. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
28/07	BioNexus Gene Lab Corp. accélère la commercialisation de la plateforme VitaGuard MRD en Asie du Sud-Est	CI

Communiqués

28/07	BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit	AQ
29/05	BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development	AQ
11/03	BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform	AQ
23/02	BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman	AQ
28/01	BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market	AQ
03/12	BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™	AQ
02/12	BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization	AQ
01/12	BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene	AQ
12/11	BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization	AQ
10/11	BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities	AQ
20/10/25	BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc.	AQ
30/07/25	BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology	AQ
30/04/25	BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness	AQ
15/04/25	BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory	AQ
07/03/25	BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy	AQ
05/03/25	BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper	AQ
25/09/24	BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.	AQ
13/09/24	BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.	AQ
12/09/24	BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions	AQ
11/09/24	BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production	AQ
27/08/24	BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd	AQ
26/08/24	BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd	AQ
18/04/24	BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare	AQ
18/04/24	BioNexus Gene Lab : Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare - Form 8-K	PU
01/04/24	BioNexus Gene Lab : Submission of Matters to a Vote of Security Holders - Form 8-K	PU